RxSight, Inc. (RXST): Price and Financial Metrics

RxSight, Inc. (RXST): $16.45

-0.08 (-0.48%)

POWR Rating

Component Grades














  • RXST scores best on the Sentiment dimension, with a Sentiment rank ahead of 98.56% of US stocks.
  • The strongest trend for RXST is in Momentum, which has been heading up over the past 177 days.
  • RXST's current lowest rank is in the Momentum metric (where it is better than 12.61% of US stocks).

RXST Stock Summary

  • RXST's went public 1.66 years ago, making it older than only 3.26% of listed US stocks we're tracking.
  • With a price/sales ratio of 11.49, RXSIGHT INC has a higher such ratio than 91.04% of stocks in our set.
  • As for revenue growth, note that RXST's revenue has grown 116.9% over the past 12 months; that beats the revenue growth of 94% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to RXSIGHT INC, a group of peers worth examining would be MOTS, AIRG, NPCE, VMEO, and SOPH.
  • To dig deeper into the stock's financial statements, go to RXST's page on browse-edgar?action=getcompany&CIK=0001111485.

RXST Valuation Summary

  • In comparison to the median Healthcare stock, RXST's price/earnings ratio is 136.21% lower, now standing at -8.4.
  • Over the past 20 months, RXST's price/sales ratio has gone down 17.4.

Below are key valuation metrics over time for RXST.

Stock Date P/S P/B P/E EV/EBIT
RXST 2023-03-24 11.5 6.3 -8.4 -9.6
RXST 2023-03-23 11.1 6.0 -8.1 -9.3
RXST 2023-03-22 10.9 6.0 -8.0 -9.2
RXST 2023-03-21 10.9 5.9 -8.0 -9.1
RXST 2023-03-20 10.7 5.8 -7.8 -9.0
RXST 2023-03-17 10.5 5.7 -7.7 -8.9

RXST Stock Price Chart Interactive Chart >

Price chart for RXST

RXST Price/Volume Stats

Current price $16.45 52-week high $17.02
Prev. close $16.53 52-week low $9.78
Day low $16.37 Volume 98,300
Day high $16.66 Avg. volume 141,634
50-day MA $14.29 Dividend yield N/A
200-day MA $13.35 Market Cap 555.62M

RxSight, Inc. (RXST) Company Bio

RxSight, Inc., a medical technology company, develops light adjustable lens (LAL) to improve uncorrected visual acuity that can be adjusted enhance uncorrected visual acuity after cataract surgery. It also offers RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is based in Aliso Viejo, California.

RXST Latest News Stream

Event/Time News Detail
Loading, please wait...

RXST Latest Social Stream

Loading social stream, please wait...

View Full RXST Social Stream

Latest RXST News From Around the Web

Below are the latest news stories about RXSIGHT INC that investors may wish to consider to help them evaluate RXST as an investment opportunity.

How Much Upside is Left in RxSight, Inc. (RXST)? Wall Street Analysts Think 25.69%

The consensus price target hints at a 25.7% upside potential for RxSight, Inc. (RXST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Yahoo | March 13, 2023

RxSight, Inc. (NASDAQ:RXST) Q4 2022 Earnings Call Transcript

RxSight, Inc. (NASDAQ:RXST) Q4 2022 Earnings Call Transcript March 6, 2023 Operator: Good day and thank you for standing by. Welcome to the RxSight Fourth Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. Please be advised that today’s conference […]

Yahoo | March 8, 2023

Q4 2022 Rxsight Inc Earnings Call

Q4 2022 Rxsight Inc Earnings Call

Yahoo | March 7, 2023

RxSight, Inc.'s (NASDAQ:RXST) biggest owners are individual investors who got richer after stock soared 14% last week

Key Insights The considerable ownership by individual investors in RxSight indicates that they collectively have a...

Yahoo | March 7, 2023

RxSight, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results

ALISO VIEJO, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months and full year ended December 31, 2022. Key Quarterly and Full Year Highlights Recognized fourth quarter 2022 revenue of $16.1 million, an increase of 91% compared to the fourth quarter of 2021, reflecting: The sale of 57 Light

Yahoo | March 6, 2023

Read More 'RXST' Stories Here

RXST Price Returns

1-mo 25.29%
3-mo 29.83%
6-mo 37.08%
1-year 32.88%
3-year N/A
5-year N/A
YTD 29.83%
2022 12.62%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7833 seconds.